Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Brown-Forman Corporation Class B — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.75 (market cap $4.49B), while Brown-Forman Corporation Class B trades at $25.7. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Brown-Forman Corporation Class B nearer its low. Which is the better fit depends on your goals.
| ACAD | BF.B | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $31.26 |
52-Week Low | $20.06 | $22.80 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BF.B trades at $25.91, down 0.92% on the day, with a bearish technical outlook per moving averages. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 beating the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings.
The stock faces near-term pressure from technical weakness, but earnings resilience offers fundamental support. Risks include execution challenges and market sentiment shifts. Upside depends on sustained earnings outperformance and positive analyst revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
